GLYKO BIOMEDICAL LTD
10KSB/A, 1996-07-29
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: OPTICAL SENSORS INC, 10-Q, 1996-07-29
Next: ASYST TECHNOLOGIES INC /CA/, DEF 14A, 1996-07-29



                  U.S. Securities and Exchange Commission
                        Washington, D.C. 20549

                            AMENDMENT NO. 2 
                                  TO
                             FORM 10-KSB

(Mark One)
[X]	Annual Report Under  Section 13 or 15(d) of the Securities 
                         Exchange Act of 1934
		For the fiscal year ended December 31, 1995

[ ]	Transition Report Pursuant to Section 13 or 15(d) of the Securities
                         Exchange Act of 1934
	            Commission File Number: 0-21994

                         GLYKO BIOMEDICAL LTD.
      (Exact name of small business issuer as specified in its charter)

          Canada					68-0230537
(State of other jurisdiction of		(I.R.S. Employer Identification No.)
incorporation or organization)

 81 Digital Drive, Novato, California		           94949
(Address of principal executive offices)               	(Zip Code)

Registrant's telephone number: (415) 382-6653
	    Securities registered under Section 12(g) of the Exchange Act:
                       Common Stock, no par value
                           (Title of Class)

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.   
Yes	 X      No
	--		--
		          
Check if there is no disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrant's knowledge, in definitive proxy or 
information statements incorporated by reference in Part III to the Form 10-KSB
or any amendment to this Form 10-KSB. ______

State issuer's revenues for its most recent fiscal year. $1,568,810.  

The approximate aggregate market value of the voting stock held by
non-affiliates computed by reference to the price at which the stock was
sold, or the average bid and asked prices of such stock, as of February 29,
1996 was $3,546,857.      

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:  14,567,944 common shares outstanding
as of February 29, 1996.

NOTE:	This Amendment is filed solely for the purpose of including pages of
Exhibit 10.14 (Exhibit C thereof) that were erroneously omitted from Amendment
No. 1 of this filing.  This Amendment NO. 2 therefore consists solely of the
full text of Exhibit C of Exhibit 10.14. 



EXHIBIT C - LIMITED WARRANTY

The following two (3) pages are taken from the FACE( Imager User's Manual
Version Dated 16 March 1994.  The Warranty Language appears on the second
of the two (2) pages following this page.  

The remainder of this page in intentionally left blank.





FACE User's Guide
Imager and Software Operations  





















Version 2.3

Copyright 1992, 1993, 1994 All rights reserved, Glyko Inc.

81 Digital Dr, Novato CA 94949

Phone 1-800-33-GLYKO (1-800-334-5956) or 1-415-382-6653

8:30 AM- 5:30 PM PT

Fax 1-415-382-7889   



FACE  WARRANTY

FACE WORKSTATION AND COMPONENTS

FACE IMAGER
	Glyko warrants the FACE imager to be free from defects in material and
	workmanship when used under normal laboratory conditions for a period
	of one year from the date of delivery. This warranty covers parts and
	labor for the first 90 days and then parts only for the remainder of
	the warranty period.

Dell COMPUTER

	One year on site parts and service provided by Dell Computers.

NOT COVERED

	This warranty does not cover systems or components which have been
	abused or have undergone unauthorized repair. This warranty does not
	cover the cost of shipping items to Glyko.

NO OTHER WARRANTIES

	Glyko disclaims all other warranties, either expressed or implied. 

LIMIT OF LIABILITY

	In no event shall Glyko be liable for damages whatsoever. This includes
	without limitation, damages for loss of business profits, business
	interruption, loss of business information, loss of sample materials or
	any other consequential or pecuniary loss which may arise from the use
	or inability to use the FACE system and components.
 

REPAIR TURN AROUND
 
	Glyko will attempt to keep turn around times to 2 weeks and under on
	Imager repairs. 




READ CAREFULLY					Glyko, Inc.

Single User License Agreement

This Agreement is a legal contract between you ("end user") and Glyko, Inc.
("Glyko").  By opening the sealed disk package you have indicated your
acceptance of the terms of this agreement.  If you do not agree to the terms
of this agreement, promptly return the unopened package to Glyko, Inc.,
81 Digital Dr., Novato, CA 94949 for a full refund.

1.) LICENSE GRANT,
	Glyko grants you the right to use one copy of the
	enclosed FACE(R) software program ("software") on
	a single computer.  Purchase of a separate License
	is required for use on an additional computer or
	distribution on a Network for use by one or more
	networked computers.

2.)COPYRIGHT,
	This software is protected by United States copyright laws
	and international treaty provisions.  As such you may make one
	copy of the software for backup purposes only.
 
3.)OTHER RESTRICTIONS,
	You may not rent, lease or network the software.  You may not
	reverse engineer, decompile or disassemble the software.  You may
	not create derivative works based on the copyrighted design of the
	software.

4.)LIMITED WARRANTY,
	Glyko warrants that the enclosed software will perform as documented
	for a period of 90 days from the date of receipt.

5.)NO OTHER WARRANTIES,
	Glyko disclaims all other warranties, either expressed or implied.

6.)LIMIT OF LIABILITY,
	In no event shall Glyko be liable for damages whatsoever.  This
	includes without limitation, damages for loss of business profits,
	business interruption, loss of business information, loss of sample
	materials or any other consequential or pecuniary loss which may 
	arise from the use or inability to use the software.




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission